Identifying vulnerabilities in the long-lived HIV reservoir to accelerate its decay
识别长期艾滋病毒储存库的脆弱性以加速其腐烂
基本信息
- 批准号:10673309
- 负责人:
- 金额:$ 108.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcuteAffectAnti-Retroviral AgentsAntibodiesAntigen PresentationAntigensAutologousBCL2 geneBCL2L1 geneBiological AssayCD4 Positive T LymphocytesCellsCharacteristicsChromatinClonal ExpansionClonalityCoupledCouplesCryopreservationDataEarly DiagnosisEnsureFOXO3A geneFutureGenetic TranscriptionGenomeGoalsHIVHIV GenomeHIV InfectionsHIV envelope proteinHalf-LifeImmunologicsIndividualInfectionLeukapheresisLigandsLongterm Follow-upMaintenanceMeasuresMediatingMemoryMolecularNCOA6 geneNatureParticipantPersonsPharmaceutical PreparationsPhenotypePredispositionProcessProductionProliferatingProteomeProvirusesRandomizedReportingResistanceSamplingSerpinsSourceTestingTimeTransforming Growth Factor betaViralViral GenomeViruscohortdecay accelerationexperimental studyfitnessgenome sequencingimmune checkpointimmune clearanceintegration sitenovel strategiesresponsetoolwhole genome
项目摘要
PROJECT SUMMARY
Latently infected CD4+ T cells harboring integrated and replication-competent HIV genomes persist during ART
and are the main obstacle to HIV eradication. In most people with HIV (PWH), the reservoir is extremely stable
with a half-life of over 3 years. All prior attempts to significantly reduce its size or accelerate its decay have failed.
Using samples from participants in the MERLIN clade B primary HIV infection cohort (Lima, Peru), we observed
5 to 10-times faster decay of the HIV reservoir in individuals initiating ART during the first 3 months of infection
compared to those randomized to start ART later, suggesting that HIV-infected cells in people treated early are
more susceptible to elimination. Differences in the half-life of the reservoir, which are maintained during at least
the first 4 years of ART, offer a unique opportunity to identify mechanisms that could be harnessed to reduce the
reservoir in all PWH on ART. In this project, we propose to unravel the cellular and viral features responsible for
the rapid clearance or long-term persistence of individual HIV reservoir cells. We will test the hypothesis that the
capacity of reservoir cells to persist for prolonged periods is driven by a combination of cellular and viral features,
which differ between early and late treated individuals and result in differential reservoir decay. We will take
advantage of the unique MERLIN cohort to study HIV reservoir cells in 12 participants who initiated ART less
than 3 months after HIV acquisition (early ART: rapid decay) and 12 participants who deferred treatment for 6
months (late ART: slow decay). We will study the early, intermediate and late reservoirs, using cryopreserved
leukaphereses (collected at 1 & 2-3 years of ART) and newly collected leukapheresis from the same continually-
suppressed participants at >7 years of ART. In Aim 1, we will test the hypothesis that intrinsic cellular features
of HIV reservoir cells underlie differences in reservoir decay. We will employ a single cell approach to identify
pro-survival factors associated with reservoir stability (Bcl-2, TCF-1, FOXO3A etc.) or that may protect infected
cells from immune clearance (ligands of immune checkpoint molecules, Serpin B9, TGF-β). We will also evaluate
the clonality of the reservoir with the hypothesis that clonal expansions of intact genomes will be more common
in late treated participants. In Aim 2, we will test the hypothesis that specific viral characteristics also contribute
to the persistence of HIV-infected cells and will be gradually enriched over time on ART. To determine if specific
viruses are selected against during therapy, we will use an assay that couples integration site sequencing with
HIV transcription assessment, to determine the proportion of reservoir cells that are transcriptionally active. We
will use a novel approach to reconstruct molecular viral clones from the latent reservoir, and will measure the
fitness of these viruses and functionally assess their HIV proteomes. In this way, we will determine if the reservoir
is gradually enriched in proviruses encoding functional Nef and Vpu, which cause escape of antigen presentation
and impede CTL-mediated killing as well as neutralization and ADCC by autologous antibodies. Results from
this study will identify cellular and viral mechanisms that can be targeted to accelerate decay of the HIV reservoir.
项目总结
潜伏感染的具有整合和复制能力的HIV基因组的CD4+T细胞在抗逆转录病毒治疗中持续存在
是根除艾滋病毒的主要障碍。在大多数艾滋病毒携带者(PWH)中,宿主极其稳定
半衰期超过3年。之前所有大幅缩小其尺寸或加速其衰败的尝试都以失败告终。
使用来自梅林B支艾滋病毒初级感染队列(秘鲁利马)参与者的样本,我们观察到
在感染的前3个月开始抗逆转录病毒治疗的个体中,艾滋病毒蓄积物的腐烂速度要快5到10倍
与那些被随机安排在较晚开始抗逆转录病毒治疗的患者相比,这表明早期治疗的人中感染艾滋病毒的细胞
更容易被淘汰。储油层半衰期的差异,至少在
ART的头4年,提供了一个独特的机会来确定可以利用的机制,以减少
水库在所有威尔斯亲王医院的艺术上。在这个项目中,我们建议揭开细胞和病毒特征对
单个艾滋病毒储存细胞的快速清除或长期存留。我们将检验这一假设
储藏细胞长时间存活的能力是由细胞和病毒特征共同驱动的,
这在早期和晚期治疗的个体之间是不同的,并导致不同的储集层衰变。我们会带上
独特的Merlin队列在研究12名启动抗逆转录病毒治疗次数较少的参与者中的艾滋病毒储存细胞方面的优势
感染艾滋病毒后超过3个月(早期抗逆转录病毒治疗:快速衰退)和12名参与者推迟治疗6个月
几个月(晚期艺术:缓慢腐烂)。我们将研究早期、中期和晚期的储集层,使用超低温保存
白细胞(在接受抗逆转录病毒治疗1年和2-3年时采集)和新采集的白细胞连续采集-
他们压抑了7年艺术生涯的参与者。在目标1中,我们将检验这样一个假设,即固有的细胞特征
艾滋病毒储存库细胞的数量是储存库腐烂的不同之处。我们将使用单细胞方法来识别
与储集层稳定性相关的促生存因子(Bcl2、TCF1、FOXO3a等)或者可能会保护受感染的人
来自免疫清除的细胞(免疫检查点分子的配体,Serpin B9,转化生长因子-β)。我们还将评估
假设完整基因组的克隆性扩张将更加普遍
在晚期治疗的参与者中。在目标2中,我们将检验特定病毒特征也起作用的假设。
对艾滋病毒感染细胞的持久性,并将随着时间的推移在ART上逐渐丰富。确定是否特定
病毒在治疗过程中被挑选出来,我们将使用一种将整合位点测序与
HIV转录评估,以确定转录活跃的存储细胞的比例。我们
将使用一种新的方法从潜在的储存库中重建分子病毒克隆,并将测量
这些病毒的适合性,并从功能上评估它们的艾滋病毒蛋白质组。通过这种方式,我们将确定水库是否
逐渐富含编码功能性Nef和VPU的前病毒,这些前病毒导致抗原递呈逃逸
并阻止CTL介导的杀伤以及自身抗体的中和和ADCC。结果来自
这项研究将确定可以有针对性地加速艾滋病毒储存库腐烂的细胞和病毒机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicolas Chomont其他文献
Nicolas Chomont的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicolas Chomont', 18)}}的其他基金
TILDA: A new sensitive and precise assay to measure the size of the latent HIV reservoir
TILDA:一种新的灵敏且精确的检测方法,用于测量潜在 HIV 病毒库的大小
- 批准号:
8968590 - 财政年份:2015
- 资助金额:
$ 108.86万 - 项目类别:
TILDA: A new sensitive and precise assay to measure the size of the latent HIV reservoir
TILDA:一种新的灵敏且精确的检测方法,用于测量潜在 HIV 病毒库的大小
- 批准号:
8880118 - 财政年份:2015
- 资助金额:
$ 108.86万 - 项目类别:
Purging the latent HIV reservoir at ART initiation: A new eradication strategy
在开始 ART 时清除潜伏的 HIV 病毒库:新的根除策略
- 批准号:
8842344 - 财政年份:2014
- 资助金额:
$ 108.86万 - 项目类别:
Purging the latent HIV reservoir at ART inititation: A new eradication strategy
在 ART 启动时清除潜伏的 HIV 病毒库:新的根除策略
- 批准号:
9060627 - 财政年份:2014
- 资助金额:
$ 108.86万 - 项目类别:
Mechanisms of HIV persistence in distinct memory CD4+ T cell subsets in blood and
HIV在血液和血液中不同记忆CD4 T细胞亚群中持续存在的机制
- 批准号:
8880560 - 财政年份:2014
- 资助金额:
$ 108.86万 - 项目类别:
TILDA: A new sensitive and precise assay to measure the size of the latent HIV re
TILDA:一种新的灵敏且精确的检测方法,可测量潜伏 HIV 病毒的大小
- 批准号:
8767463 - 财政年份:2014
- 资助金额:
$ 108.86万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 108.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 108.86万 - 项目类别:
Operating Grants














{{item.name}}会员




